Abilify安立復

Abilify

aripiprazole

Manufacturer:

Otsuka

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Aripiprazole
Indications/Uses
Treatment of schizophrenia. Treatment & maintenance of manic or mixed episodes associated w/ bipolar I disorder as monotherapy or adjunctive to lithium or valproate. Adjunctive treatment of major depressive disorder. Treatment of irritability associated w/ autistic disorder.
Dosage/Direction for Use
Schizophrenia Adult 10 or 15 mg/day, may be increased at intervals of not <2 wk. Adolescent 13-17 yr Initially 2 mg/day, titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Bipolar disorder Adult Monotherapy: Initially 15 mg. Adjunctive therapy: 10-15 mg w/ lithium or valproate. Maintenance: Same dose needed to stabilize patients during acute treatment. Childn 10-17 yr Initially 2 mg/day, titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Adjunctive treatment of major depressive disorder Adult Initially 2-5 mg/day. Dose range: 2-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not <1 wk. Irritability associated w/ autistic disorder Childn 6-17 yr Initially 2 mg/day, may be increased to 10-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not <1 wk.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Dementia-related psychoses (especially in the elderly).
Special Precautions
Increased mortality & incidence of cerebrovascular adverse reactions (eg, stroke) in elderly w/ dementia-related psychosis. Development of neuroleptic malignant syndrome. Tardive dyskinesia after long-term treatment. Hyperglycemia & DM. Conditions which would predispose patients to hypotension. Leukopenia, neutropenia & agranulocytosis. Frequent monitoring of complete blood count during the 1st few mth of therapy. Discontinue at the 1st sign of clinically significant decline of WBC. History of seizures or w/ conditions that lower seizure threshold. May impair ability to drive or operate machinery. Patients who will be experiencing conditions which may contribute to an elevation in core body temp or being subject to dehydration. Risk for aspiration pneumonia. Monitor behavior change & clinical worsening of depression & suicide risk. Risk of pathological gambling & other compulsive behaviours. Patients w/ concomitant illness. Pregnancy & lactation.
Adverse Reactions
Nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, restlessness, somnolence, tremor, sedation, extrapyramidal disorder.
Drug Interactions
Use w/ caution in combination w/ other centrally-acting drugs & alcohol. May enhance the effect of some antihypertensives. CYP3A4 inducers (eg, carbamazepine) may increase aripiprazole clearance. CYP3A4 & CYP2D6 inhibitors (eg, ketoconazole, itraconazole; quinidine, fluoxetine or paroxetine) may inhibit aripiprazole elimination.
MIMS Class
Antipsychotics
ATC Classification
N05AX12 - aripiprazole ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Abilify tab 2 mg
Packing/Price
30's
Form
Abilify tab 5 mg
Packing/Price
30's
Form
Abilify tab 10 mg
Packing/Price
30's
Form
Abilify tab 15 mg
Packing/Price
30's
Form
Abilify Discmelt orally disintegrating tab 10 mg
Packing/Price
30's
Form
Abilify Discmelt orally disintegrating tab 15 mg
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in